Thus, the targeting of PRMT5/MEP50 activity significantly induced the suppression of cell growth and the degradation of client proteins AKT and NEMO in NDRG2low ATL and other cancer cells (Figure 7B). This evidence concerns the gene PRMT5 and cancer.